Educational Activities Archives

Join us for this evidence-based course that cuts through the confusion, dispels longstanding myths, and gives you the practical knowledge to make confident, compassionate treatment decisions. You will leave with a clear understanding of when and how to use buprenorphine or methadone, how to employ shared-decision making with patients through the realities of neonatal withdrawal, and how to build a postpartum care plan that supports both mother and child long after delivery. Whether you are new to this patient population or looking to sharpen your clinical approach, this course meets you where you are and empowers you to do more.

Opioids are commonly prescribed for chronic pain, but are also associated with a risk for serious harms, including overdose and opioid use disorder. This course reviews risk factors for opioid misuse, opioid use disorder, and overdose in patients with chronic pain, explains methods for screening and assessing for problematic opioid use, reviews methods for mitigating risks associated with prescribed opioids, and details non-opioid treatment approaches for pain. The course is based on principles in the Center for Disease Control and Prevention’s guideline on opioids for chronic pain and reviews recent evidence on benefits and harms of opioids.

Opioid use disorder (OUD) has highly effective FDA-approved medications for its treatment. This course reviews and compares pharmacological treatment options for individuals with OUD, including methadone, buprenorphine (sublingual and injectable formulations), and naltrexone (oral and long-acting intramuscular formulations). Current evidence for each medication is reviewed in detail, and studies comparing each are discussed. The purpose and goal of medications for OUD are reviewed, and different treatment models are presented. The course includes case vignettes in which medication options for OUD are considered.

This webinar will explore the intersection of substance use and veteran status, examining the impact of post-traumatic stress, moral injury, and systemic barriers to care. Participants will learn about evidence-based interventions, and resources available to veterans.

Over 2.5 million adults in the U.S. are diagnosed with OUD. In 2022, 12.7% of ED visits involved opioids. Yet only 25% of those who need treatment receive recommended MOUD. MOUDs are highly effective treatments that have been shown to decrease opioid use, cravings and transmission of infectious disease, and to increase retention in treatment. As the opioid epidemic continues to impact people across the U.S., the ED represents a critical access point to the health care system, supporting people with OUD by initiating MOUD, such as buprenorphine, and connecting them to low-threshold, easy-to-access care for continued treatment.

Due to the opioid epidemic, over 2.5 million adults in the U.S. have opioid use disorder (OUD), yet only 25% of those who need treatment receive recommended medication for opioid use disorder (MOUD). Alongside the rising rates of OUD, there has been an increase in infectious diseases such as HIV, hepatitis B and C, endocarditis and skin and soft-tissue infections, particularly among people who inject drugs. These intertwining epidemics have not been sufficiently addressed, but MOUD — combined with appropriate substance use treatment supports and health care services — represents an opportunity to reduce risk and improve health outcomes.